The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISA 2022 | Current and emerging antibody-based immunotherapies in AL amyloidosis
Maximilian Steinhardt, MD, University Hospital Würzburg, Würzburg, Germany, comments on the efficacy of currently available and emerging antibodies in the treatment of AL amyloidosis, including daratumumab, elotuzumab, and antibodies targeting amyloid deposits. This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
